APP (amyloid beta precursor protein; HGNC:620, NCBI Gene 351) is the gene on chromosome 21q21.3 encoding the amyloid precursor protein — a ubiquitous transmembrane protein whose sequential cleavage by β- and γ-secretases releases the amyloid-β peptide (Aβ40/Aβ42) that aggregates into the plaques of Alzheimer's disease. Its duplications and missense mutations cause familial early-onset Alzheimer's, and trisomy 21's extra copy explains the Alzheimer pathology that people with Down syndrome develop by middle age — the gene-dosage proof of the amyloid cascade.
Approved Symbol
APP (HGNC:620)
Chromosomal Locus
21q21.3
Encoded Product
APP — a 110–130-kDa single-pass transmembrane glycoprotein (695–770 aa isoforms)
Genomic organization: 18 exons with alternative splicing (APP695 neuronal-dominant, APP751/770 with a Kunitz-protease-inhibitor domain); the Aβ region spans the transmembrane boundary — exons 16–17 — where the familial mutations cluster around the secretase cleavage sites.
Expression: Neurons express it highly, with axonal transport delivering APP along neurons; physiological roles include synapse formation, neuroprotection after injury, and (via its secreted ectodomain, sAPPα) trophic signaling — the normal functions the amyloid program overshadows.
Molecular Function & Pathways
Cleavage competition: The non-amyloidogenic route (α-secretase cuts within Aβ, then γ) produces sAPPα and harmless fragments; the amyloidogenic route (β- then γ-secretase) releases Aβ — the Swedish mutation (KM670/671NL) at the β-site raising total Aβ, the Arctic and Dutch mutations promoting aggregation, γ-site mutants shifting the ratio toward the 42-residue, aggregation-prone species.
Amyloid to tau: Aβ oligomers' synaptotoxicity engages tau phosphorylation and spread — the amyloid cascade hypothesis's two acts, with the hippocampus-to-cortex spread following Braak staging.
Clinical & Therapeutic Significance
Cancer genetics: APP duplications (and the triplication of Down syndrome) cause autosomal-dominant Alzheimer's with cerebrovascular amyloid — dosage, not just mutation, suffices; APP mutations account for a minority of familial Alzheimer's (PSEN1/2 carrying most).
Therapeutics: Anti-Aβ monoclonal antibodies (lecanemab, donanemab) removing aggregated amyloid and slowing decline in early disease — the cascade hypothesis finally validated therapeutically; γ-secretase modulators and β-site inhibitors' historical failures mapping the target's complexity.